Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 19, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a financial results report.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data present relates to a specific share transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.285 per share.
- Aggregated Volume: 1,747.278 shares.
Material Changes
The filing reports an increase in the notional interest in Ordinary Shares for Dr. P J T Vallance, President of Pharmaceuticals R&D. This increase resulted from the re-investment of dividends paid on July 14, 2016, under the Company's 2009 Deferred Annual Bonus Plan. The transaction included both personal contributions and matching shares.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on business performance, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of an insider share transaction.
Investor Verification Points
- Verify the total shareholding of Dr. P J T Vallance following this transaction to assess insider confidence.
- Confirm the terms of the 2009 Deferred Annual Bonus Plan to understand the matching share mechanism.
- Note that this filing contains no operational or financial performance data for the period.